First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with BRAFV600-mutated low-grade glioma, a phase 2 trial suggests.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.